Table 5.
Semiquantitative SUV measurements in relation to the presence of FRI
| All 18F-FDG PET/CT scans (N = 155)a | 18F-FDG PET/CT scans positive for FRI (N = 61)a | 18F-FDG PET/CT scans negative for FRI (N = 94) | p value | |
|---|---|---|---|---|
| 18F-FDG dose (MBq) | 193.0 (77.0) | 199.0 (132.0) | 192.0 (70.0) | 0.287 |
| Blood glucose (mmol/l) | 5.6 (1.0) | 5.7 (0.9) | 5.5 (1.1) | 0.241 |
| SUVmax | ||||
| Infection location | 4.2 (3.4) | 5.9 (3.5) | 3.2 (2.5) | <0.001 |
| Contralateral location | 1.7 (0.7) | 1.8 (0.9) | 1.7 (0.7) | 0.039 |
| Ratiosb | ||||
| Infection/Contralateral | 2.1 (1.8) | 3.0 (2.1) | 1.9 (1.4) | <0.001 |
| Infection/Muscle | 4.6 (3.9) | 6.4 (4.9) | 3.5 (3.0) | <0.001 |
| SUVpeak | ||||
| Infection location | 3.5 (2.7) | 4.7 (2.4) | 2.6 (1.9) | <0.001 |
| Contralateral location | 1.4 (0.7) | 1.5 (0.7) | 1.4 (0.7) | 0.070 |
| Ratiosb | ||||
| Infection/Contralateral | 2.1 (1.8) | 2.9 (2.0) | 1.8 (1.4) | <0.001 |
| Infection/Muscle | 4.1 (3.4) | 5.5 (3.6) | 3.3 (2.9) | <0.001 |
Data are presented as medians (IQR)
FRI fracture-related infection
aSUV measurements could not be retrieved in one patient for technical reasons.
bRatios were calculated by dividing the SUV of the suspected infected area by the SUV of the contralateral area/nearby muscle; a value of >1 signifies higher uptake in the suspected infected area.